Press Releases
CASI Pharmaceuticals Enters Strategic Partnering And Contract Manufacturing Agreement With Yiling Wanzhou International Pharmaceuticals For Entecavir And Cilostazol
CASI Pharmaceuticals, Inc , a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients...
News
Aquinnah Pharmaceuticals Receives $3.4M Grant from NINDS To Advance New Therapies for ALS
Aquinnah Pharmaceuticals, leaders in stress granule biology, an exciting new target for the development of neuro degenerative therapeutics, announced that it has been awarded...
Clinical Trials
Aminex Therapeutics Initiates First Clinical Trial of Novel Immunotherapy AMXT 1501 + DFMO in Cancer Patients
Aminex Therapeutics, Inc., a clinical-stage drug development company focused on advancing a novel cancer immunotherapy, announced it received clearance from the FDA to initiate...
Press Releases
Processa Pharmaceuticals Receives Orphan Designation Status For PCS499 In Necrobiosis Lipoidica From The FDA
Processa Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have a high...
Press Releases
ChargePoint Technology Reinforces Asia Presence withGrowth in China and Japan
Powder containment and aseptic transfer valve specialist, ChargePoint Technology has achieved triple-digit growth in key Asian markets and will be exhibiting its sterile and...
News
LANXESS: Price adjustment for PA 6.6 compounds
LANXESS is raising its prices for Durethan A (polyamide 6.6) compounds in Europe, Middle East and Africa by EUR 0.60/kg with immediate effect. ...
Press Releases
Aptar Pharma’s Preservative-Free Multidose Dispenser Approved for Anti-Allergy Treatment by French Regulatory Agency ANSM
Aptar Pharma’s innovative, preservative-free multidose Ophthalmic Squeeze Dispenser is the approved delivery device for Bausch+Lomb’sLevofree Multidose in France. This marks the...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read